Galectin Therapeutics (GALT) Gains from Investment Securities (2021 - 2026)

Galectin Therapeutics' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$983000.0 for Q1 2026.

• On a quarterly basis, Gains from Investment Securities fell 4032.0% year-over-year to -$983000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 277.36% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, up 703.06% from the prior year.
• Gains from Investment Securities retreated to -$983000.0 in Q1 2026 per GALT's latest filing, from $220000.0 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $2.2 million in Q3 2025 and bottomed at -$2.1 million in Q4 2024.
• The 5-year median for Gains from Investment Securities is $25000.0 (2025), against an average of $108823.5.
• Across the five-year window, Gains from Investment Securities jumped 1114.81% in 2025 and slumped 4032.0% in 2026, its largest moves.
• Year by year, Gains from Investment Securities stood at -$277000.0 in 2022, then slipped by 21.66% to -$337000.0 in 2023, then tumbled by 523.74% to -$2.1 million in 2024, then surged by 110.47% to $220000.0 in 2025, then slumped by 546.82% to -$983000.0 in 2026.
• Per Business Quant, the three latest GALT Gains from Investment Securities figures stand at -$983000.0 (Q1 2026), $220000.0 (Q4 2025), and $2.2 million (Q3 2025).